Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06769620 · ClinicalTrials.gov registry record · Phase 1
A First in Human Study of ORT247 in Healthy Volunteers
A Phase 1 study of Amyotrophic Lateral Sclerosis (ALS), sponsored by Orthogonal Neuroscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT06769620: Completed Phase 1 study of Amyotrophic Lateral Sclerosis (ALS), sponsored by Orthogonal Neuroscience.
NCT06769620 is a Phase 1 study of Amyotrophic Lateral Sclerosis (ALS) that has completed, run by Orthogonal Neuroscience. The registered enrollment target is 44 participants, below the 300-participant average among 18 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06769620, a Phase 1 study of Amyotrophic Lateral Sclerosis (ALS), has completed, sponsored by Orthogonal Neuroscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center, double-blinded, randomized, placebo controlled single ascending dose clinical study, with the primary purpose of evaluating the safety, tolerability, pharmacokinetics (PK), and immunohistochemistry of escalating intravenous doses of ORT247 in healthy volunteers.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ORT247
Study Locations (1)
Texas
- Worldwide Clinical Trials - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2022-06-06 |
| Est. Completion | 2023-10-24 |
| Phase | Phase 1 |
What the finished NCT06769620 record still lists
NCT06769620 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 300-participant average among 18 other Amyotrophic Lateral Sclerosis (ALS) trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis (ALS) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06769620 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06769620 about?
NCT06769620 is a clinical study titled "A First in Human Study of ORT247 in Healthy Volunteers". This is a single center, double-blinded, randomized, placebo controlled single ascending dose clinical study, with the primary purpose of evaluating the safety, tolerability, pharmacokinetics (PK), and immunohistochemistry of escalating intravenous doses of ORT247 in healthy volunteers.
What is the current status of trial NCT06769620?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2022-06-06. Estimated completion is 2023-10-24.
What conditions does trial NCT06769620 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis (ALS).
What interventions are being tested in trial NCT06769620?
The interventions under investigation include: Placebo (DRUG), ORT247 (DRUG).
Who is sponsoring clinical trial NCT06769620?
This trial is sponsored by Orthogonal Neuroscience, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06769620 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis (ALS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06769620's enrollment target sits among peer trials
44 14th of 18 higher than 5 of 18 other Amyotrophic Lateral Sclerosis (ALS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis (ALS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
RECRUITING · Phase 1
-
Intestinal Microbiome Transplant in ALS
RECRUITING · Phase 1
-
Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.
RECRUITING · NA
-
Healing ALS Registry Observational Study (HAROS)
RECRUITING
-
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
RECRUITING · Phase 2
-
Study of COYA 302 for the Treatment of ALS
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI